GMDA Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

SPRZEDAż 118571 min ago

@ $0.367

Wydano: 13 vas. 2024 @ 23:00

Zwrot: -91.09%

Poprzedni sygnał: vas. 13 - 21:29

Poprzedni sygnał: Kupno

Zwrot: 0.55 %

Live Chart Being Loaded With Signals

Commentary (5 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	23.04M
Średni wolumen	9.67M
Kapitalizacja rynkowa	4.34M
EPS	$0 ( 2024-03-27 )
Następna data zysków	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0400
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-31	Moch Kenneth I	Buy	200 000	Ordinary Shares
2024-01-31	Wills Stephen T	Buy	200 000	Ordinary Shares
2024-01-31	Tomasello Shawn	Buy	200 000	Ordinary Shares
2024-01-31	Adams Julian	Buy	200 000	Ordinary Shares
2024-01-31	Simantov Ronit	Buy	480 319	Ordinary Shares

INSIDER POWER
94.97
Last 90 transactions
Buy: 8 073 627 \| Sell: 418 674

Wolumen Korelacja

Długi: 0.12 (neutral)

Krótki: 0.82 (strong)

Signal:(73.984) Same movement expected

Gamida Cell Ltd Korelacja

10 Najbardziej pozytywne korelacje
AMRS	0.906
ATHN	0.891
BRZE	0.89
PRFT	0.882
EZGO	0.88
PTRA	0.878
ARIZ	0.873
SHCR	0.87
GSHD	0.87
LULU	0.87

10 Najbardziej negatywne korelacje
LABP	-0.944
LWAY	-0.934
IDN	-0.928
SCTL	-0.923
NN	-0.915
MESO	-0.914
CURI	-0.91
VFF	-0.908
ALR	-0.907
MOTNU	-0.906

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Gamida Cell Ltd Korelacja - Waluta/Towar

0.00
( neutral )

Gamida Cell Ltd Finanse

Annual	2023
Przychody:	$1.78M
Zysk brutto:	$-1.69M (-94.96 %)
EPS:	$-0.570

FY	2023
Przychody:	$1.78M
Zysk brutto:	$-1.69M (-94.96 %)
EPS:	$-0.570

FY	2022
Przychody:	$0
Zysk brutto:	$-440 000 (0.00 %)
EPS:	$-2.42

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$0

Financial Reports:

No articles found.

Gamida Cell Ltd

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.